280 related articles for article (PubMed ID: 12650491)
21. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.
Turner NC; Dolan JS; Grimsditch D; Lamb J; Worby A; Murray KJ; Coates WJ; Warrington BH
Br J Pharmacol; 1994 Apr; 111(4):1198-204. PubMed ID: 8032606
[TBL] [Abstract][Full Text] [Related]
22. Lack of cyclic nucleotide regulation of MBCQ-induced relaxation of rat ileal smooth muscle.
Kaneda T; Yamamoto H; Azegami Y; Shimizu K; Urakawa N; Nakajyo S
J Smooth Muscle Res; 2003 Jun; 39(3):47-54. PubMed ID: 14572172
[TBL] [Abstract][Full Text] [Related]
23. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
27. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
28. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
O'Donnell JM; Frith S
Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
[TBL] [Abstract][Full Text] [Related]
29. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat.
van Staveren WC ; Markerink-van Ittersum M ; Steinbusch HW; de Vente J
Brain Res; 2001 Jan; 888(2):275-286. PubMed ID: 11150485
[TBL] [Abstract][Full Text] [Related]
30. Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.
Velardez MO; De Laurentiis A; del Carmen Díaz M; Lasaga M; Pisera D; Seilicovich A; Duvilanski BH
Eur J Endocrinol; 2000 Aug; 143(2):279-84. PubMed ID: 10913949
[TBL] [Abstract][Full Text] [Related]
31. Comparison of responses to siguazodan, rolipram, and zaprinast in the feline pulmonary vascular bed.
De Witt BJ; Marrone JR; Kadowitz PJ
Eur J Pharmacol; 2000 Oct; 406(2):233-8. PubMed ID: 11020486
[TBL] [Abstract][Full Text] [Related]
32. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
33. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
Rabe KF; Tenor H; Dent G; Schudt C; Nakashima M; Magnussen H
Am J Physiol; 1994 May; 266(5 Pt 1):L536-43. PubMed ID: 7515580
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
Delpy E; le Monnier de Gouville AC
Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
[TBL] [Abstract][Full Text] [Related]
35. Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery.
Komas N; Lugnier C; Andriantsitohaina R; Stoclet JC
Eur J Pharmacol; 1991 Sep; 208(1):85-7. PubMed ID: 1657622
[TBL] [Abstract][Full Text] [Related]
36. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
37. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
38. Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.
Grous M; Barnette M
Br J Pharmacol; 1994 Jan; 111(1):259-63. PubMed ID: 7516803
[TBL] [Abstract][Full Text] [Related]
39. Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery.
Lillestłl IK; Helle KB; Aardal S
Scand J Clin Lab Invest; 1998 Dec; 58(8):625-34. PubMed ID: 10088199
[TBL] [Abstract][Full Text] [Related]
40. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
Johnson WB; Katugampola S; Able S; Napier C; Harding SE
Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
